Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 de » 2 d (Expand Search), _ de (Expand Search), i de (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
de decrease » we decrease (Expand Search), _ decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 de » 2 d (Expand Search), _ de (Expand Search), i de (Expand Search)
-
1041
-
1042
Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis
Published 2016“…The overall proportion of NSSPP beneficiaries dispensed a statin increased approximately 4-fold during the study period. …”
-
1043
-
1044
-
1045
-
1046
-
1047
-
1048
-
1049
-
1050
-
1051
-
1052
-
1053
-
1054
Table_1_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX
Published 2018“…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
-
1055
Table_3_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX
Published 2018“…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
-
1056
Table_4_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX
Published 2018“…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
-
1057
Image_1_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.PDF
Published 2018“…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
-
1058
-
1059
-
1060